A phase II randomized study to evaluate a new psychosocial intervention (PI) plus early palliative care (PC) in the reduction of depression of advanced cancer patients (ACP): The PREPArE trial.

被引：0
|
作者：
Paiva, Carlos Eduardo
do Carmo, Thamires Monteiro
de Oliveira, Cleyton Zanardo
Nascimento, Maria Salete de Angelis
de Siqueira, Milena Ruas
Borges, Marielle
Paiva, Bianca Sakamoto Ribeiro
机构：
[1] Barretos Canc Hosp, Barretos, Brazil
[2] Fundacao Pio XII, Barretos, Brazil
[3] Barretos Canc Hosp, Dept Palliat Care, Barretos, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e21626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21626
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment
    Van Cutsem, Eric
    Yoshino, Takayuki
    Hocke, Julia
    Oum'Hamed, Zohra
    Studeny, Matus
    Tabernero, Josep
    CLINICAL COLORECTAL CANCER, 2016, 15 (01) : 91 - 94
  • [42] Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
    Vignani, Francesca
    Tambaro, Rosa
    De Giorgi, Ugo
    Giannatempo, Patrizia
    Bimbatti, Davide
    Carella, Claudia
    Stellato, Marco
    Atzori, Francesco
    Aieta, Michele
    Masini, Cristina
    Hamzaj, Alketa
    Ermacora, Paola
    Veccia, Antonello
    Pignata, Sandro
    Lolli, Cristian
    Procopio, Giuseppe
    Pierantoni, Francesco
    Zonno, Antonia
    Santini, Daniele
    Di Maio, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
    Sohn, Joohyuk
    Kim, Gun Min
    Jung, Kyung Hae
    Jeung, Hei-Cheul
    Lee, Jieun
    Lee, Keun Seok
    Im, Seock-Ah
    Kang, Seok Yun
    Kim, Se Hyun
    Kim, Han Jo
    Park, Kyong Hwa
    Chae, Yee Soo
    Koh, Su-Jin
    Cho, Eun Kyung
    Park, Keon Uk
    Lee, Sung Sook
    Kim, Ji-Yeon
    Choi, In Sil
    Baek, Sun Kyung
    Moon, Yong Wha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA502 - LBA502
  • [44] A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT -ov-10) and Gynecologic Cancer Intergroup (GCIG) trial.
    Pignata, Sandro
    Scambia, Giovanni
    Lauria, Rossella
    Raspagliesi, Francesco
    Panici, Pierluigi Benedetti
    Cormio, Gennaro
    Katsaros, Dionyssios
    Sorio, Roberto
    Cavazzini, Giovanna
    Ferrandina, Gabriella
    Breda, Enrico
    Murgia, Viviana
    Sacco, Cosimo
    Sierra, Nuria Maria Asensio
    Pisano, Carmela
    Salutari, Vanda
    Weber, Beatrice E.
    Pujade-Lauraine, Eric
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [45] A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicentre Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10)-Gynecologic Cancer Intergroup (GCIG) trial.
    Pignata, Sandro
    Scambia, Giovanni
    Lauria, Rossella
    Raspagliesi, Francesco
    Panici, Pierluigi Benedetti
    Cormio, Gennaro
    Katsaros, Dionyssios
    Sorio, Roberto
    Cavazzini, Giovanna
    Ferrandina, Gabriella
    Breda, Enrico
    Murgia, Viviana
    Sacco, Cosimo
    Sierra, Nuria Maria Asensio
    Pisano, Carmela
    Salutari, Vanda
    Weber, Beatrice E.
    Pujade-Lauraine, Eric
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).
    Yu, Evan Y.
    Fling, Steven
    Salim, Bob
    Sweis, Randy F.
    Chatta, Gurkamal S.
    Jain, Rohit K.
    Delacroix, Scott Edward
    Moon, Helen
    Lacroix, Andreanne
    Kaiser, Judith C.
    Sharon, Elad
    Cheever, Martin A.
    Pachynski, Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)
    Goss, Glenwood
    Ferry, David
    Laurie, Scott
    Wierzbicki, Rafal
    Thompson, Joyce
    Biesma, B.
    Duffield, Emma
    Ghiorghiu, Serban
    Zarenda, Marc
    Armour, Alison
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S340 - S340
  • [48] Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)
    Pellegrino, Benedetta
    Tommasi, Chiara
    Serra, Olga
    Gori, Stefania
    Cretella, Elisabetta
    Ambroggi, Massimo
    Frassoldati, Antonio
    Bisagni, Giancarlo
    Casarini, Chiara
    Bria, Emilio
    Carbognin, Luisa
    Fiorio, Elena
    Mura, Antonella
    Zamagni, Claudio
    Gianni, Lorenzo
    Zambelli, Alberto
    Montemurro, Filippo
    Tognetto, Michele
    Todeschini, Renata
    Missale, Gabriele
    Campanini, Nicoletta
    Silini, Enrico Maria
    Maglietta, Giuseppe
    Musolino, Antonino
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [49] Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naive patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial
    Takeno, Atsushi
    Makari, Youichi
    Endo, Shunji
    Matsuyama, Jin
    Kawabata, Ryohei
    Sugimoto, Naotoshi
    Taniguchi, Hirokazu
    Nagai, Kenichi
    Tamura, Shigeyuki
    Nishijima, Junichi
    Ueda, Shugo
    Kimura, Yutaka
    Tamura, Takao
    Kobayashi, Kenji
    Kawakami, HIsato
    Fujitani, Kazumasa
    Sakai, Daisuke
    Shimokawa, Toshio
    Kurokawa, Yukinori
    Satoh, Taroh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)
    Vergnenegre, Alain
    Tillon, Julie
    Corre, Romain
    Barlesi, Fabrice
    Berard, Henri
    Vernejoux, Jean-Marc
    Le Caer, Herve
    Fournel, Pierre
    Marin, Benoit
    Chouaid, Christos
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 364 - 370
12345